^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JSKN003

i
Other names: JSKN003
Associations
Company:
Alphamab
Drug class:
Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
Associations
7ms
New P3 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
gemcitabine • paclitaxel • docetaxel • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate • JSKN003
10ms
To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=300, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting | Phase classification: P1a/1b --> P1/2
Enrollment open • Phase classification
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 expression
|
JSKN003
1year
To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1a/1b, N=365, Not yet recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
HER-2 positive • HER-2 mutation • HER-2 expression • BRAF wild-type • HER-2 exon 19 mutation
|
JSKN003
over1year
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors (clinicaltrials.gov)
P1, N=45, Recruiting, Alphamab (Australia) Co Pty Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
JSKN003
over1year
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
JSKN003